Price to sales forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS
The article discusses the price to sales forward metric for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of financial information available for the company.
Enterprise value to EBITDA forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS
This article provides the enterprise value to EBITDA forward for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS). It lists key financial data for the company, accessible through TradingView, and indicates that the market is currently closed.
Price to earnings forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS
This article provides financial information for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), specifically focusing on its price to earnings forward. It indicates that no trades were made and the market is closed, suggesting the data presented is statistical rather than real-time trading activity. The content is primarily a data page from TradingView, detailing various financial metrics and general information about the company.
Did Copay Allegations and New Director Equity Awards Just Shift Tarsus Pharmaceuticals' (TARS) Investment Narrative?
A recent short report by Culper Research has raised concerns about Tarsus Pharmaceuticals' Medicare copay practices, potentially altering its investment narrative. Simultaneously, new equity awards for non-employee directors aim to align their incentives with long-term shareholder interests, especially as regulatory scrutiny on reimbursement emerges. This analysis explores how these developments might impact Tarsus's financial outlook and fair value, which previously projected significant revenue and earnings growth.
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) shares rose 7.5% due to strong investor confidence in its product Xdemvy, which saw significant sales growth and global expansion. The company also has a promising pipeline with mid-stage studies for TP-04 and TP-05, with topline data expected in mid-2027. Despite positive revenue forecasts, the unaltered consensus EPS estimate over the last 30 days suggests investors should monitor future earnings estimate revisions for sustained strength.
TARS - Tarsus Pharmaceuticals Inc Short Interest
This article provides comprehensive financial data for Tarsus Pharmaceuticals Inc (TARS), including its latest stock performance, market capitalization, key financial ratios, and short interest figures. It details EPS, sales growth, insider/institutional ownership, and various performance metrics over different timeframes, highlighting a recent closing price of $65.44.
Did Copay Allegations and New Director Equity Awards Just Shift Tarsus Pharmaceuticals' (TARS) Investment Narrative?
A recent short seller report by Culper Research has raised concerns about Tarsus Pharmaceuticals' Medicare copay practices, while the company also issued new equity awards to its non-employee directors. These developments could significantly influence the investment narrative around Tarsus, especially considering the existing focus on XDEMVY's adoption and pipeline diversification. The director equity awards, tied to share price and continued service, suggest an intent to align director incentives with long-term shareholder interests amidst regulatory scrutiny.
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme
Tarsus Pharmaceuticals (TARS) shares dropped after Culper Research alleged the company is using an illegal Medicare copay scheme to boost sales of its sole product, XDEMVY, and heavily inflated its total addressable market. Culper claims Tarsus's donations to a specific health foundation effectively funded copay assistance for Medicare patients, violating anti-kickback statutes. Despite retail traders dismissing these claims due to Culper's past shorting record, the report predicts Tarsus will miss its 2026 guidance, while the company claims XDEMVY will make peak sales of $2 billion.
Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares Fall
Tarsus Pharmaceuticals' shares fell significantly after Culper Research accused the company of manipulating Medicare beneficiaries' copays for its eye drug, Xdemvy. Culper alleges that Tarsus orchestrated a scheme to make Medicare patients' copays appear lower, violating federal guidelines and leading to potential recoupments. The report indicates that Tarsus uses an "alternative funding program" to cover copays, effectively preventing patients from reaching their deductibles and out-of-pocket maximums.
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme
Tarsus Pharmaceuticals' stock has dropped following allegations from short-seller Culper Research about an illegal Medicare copay scheme and an overinflated addressable market for its drug XDEMVY. Culper claims Tarsus channeled donations to a foundation to cover Medicare patient copays, violating anti-kickback statutes, and that the company's projected peak revenues are significantly overstated. These claims have led to skepticism about Tarsus's 2026 profit estimates and its market valuation.
Tarsus (TARS) director awarded RSUs and options for 6,254 shares
Tarsus Pharmaceuticals, Inc. director Andrew D. Goldberg was granted 2,417 Restricted Stock Units (RSUs) and stock options for 3,837 shares as part of his compensation for serving as a non-employee director. These equity awards, totaling 6,254 shares, were issued in connection with the company's 2026 annual meeting of stockholders. Both the RSUs and options will fully vest on the one-year anniversary of the grant date, contingent on his continuous board service, with the stock option having an exercise price of $64.34 per share.
Equity awards grant Tarsus (TARS) director RSUs and stock options
Tarsus Pharmaceuticals, Inc. director Bhaskar Chaudhuri received equity awards including 2,417 Restricted Stock Units and a stock option for 3,837 shares with an exercise price of $64.34. These awards serve as compensation for his role as a non-employee director, vesting in full on the one-year anniversary of the June 25, 2026 grant date, contingent on continuous service. This information was reported in a Form 4 SEC filing.
Form 4 Tarsus Pharmaceuticals Inc For: 29 June By Investing.com
This article from Investing.com announces the filing of a Form 4 by Tarsus Pharmaceuticals Inc. on June 29. The document, which typically reports changes in beneficial ownership of company stock by insiders, is presented without further specific details but includes real-time market data for various indices, commodities, and stocks. The company's stock symbol is TARS, and it showed a 7.47% increase at the time of publication.
Tarsus (TARS) director Wendy Yarno receives RSU and option grants as board pay
Tarsus Pharmaceuticals director Wendy L. Yarno (TARS) received equity awards as part of her compensation for the company’s 2026 annual meeting. She was granted 1,209 and 2,417 restricted stock units (RSUs) and an option for 3,837 shares at an exercise price of $64.34. These grants are for her continued board service and are not open-market transactions.
Tarsus Pharmaceuticals (TARS) grants director RSUs and stock options
Tarsus Pharmaceuticals director Morrison Scott W received 2,417 Restricted Stock Units and 3,837 stock options as compensation for his service. These equity awards, granted on June 25, 2026, will fully vest on their one-year anniversary, contingent on his continuous service. The stock options have an exercise price of $64.34 per share.
Tarsus (NASDAQ: TARS) holders back board, pay and auditor
Tarsus Pharmaceuticals, Inc. held its annual stockholder meeting on June 25, 2026, where shareholders elected four Class III directors, approved executive officer compensation on an advisory basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026. A substantial majority of votes supported all proposals, indicating strong shareholder confidence in the company's governance and management.
Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants
Tarsus Pharmaceuticals director Katherine Goodrich received 2,417 restricted stock units (RSUs) and stock options for 3,837 shares as part of her non-employee director compensation. These equity awards, granted on June 25, 2026, with an option strike price of $64.34, will vest in full one year from the grant date, contingent on her continued board service. The Form 4 filing details these grants, clarifying they are compensation and not open-market purchases.
(TARS) and the Role of Price-Sensitive Allocations
This article analyzes Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) and its price-sensitive allocations. It highlights strong sentiment across all time horizons supporting an overweight bias, an exceptional risk-reward setup targeting a 22.6% gain, and outlines specific institutional trading strategies including position, momentum breakout, and risk hedging. Multi-timeframe signal analysis also indicates strong signals for near-term, mid-term, and long-term horizons for TARS.
Tarsus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TARS)
This article provides an overview of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) stock performance, financial actuals, and analyst estimates. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates, along with insights into revenue and net income figures.
TARS Forecast — Price Target — Prediction for 2027
This article provides an overview of Tarsus Pharmaceuticals, Inc. (TARS) stock, including analyst price targets, historical performance, and financial data. Nine analysts have provided 1-year price forecasts, with estimates ranging from $88.00 to $100.00. The company's stock has shown significant growth over the past year and last reported earnings exceeded expectations.
Tarsus Pharmaceuticals Inc (TARS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Tarsus Pharmaceuticals Inc (TARS), detailing its price momentum score, current support and resistance levels, and insights from various technical indicators and moving averages. While the stock currently trades between resistance at $67.10 and support at $58.01, suitable for range-bound swing trading, its overall technical rating leans towards "Buy" according to moving averages despite mixed signals from individual indicators.
Tarsus (TARS) CEO Azamian sells 10,000 shares via 10b5-1 trading plan
Tarsus Pharmaceuticals CEO Bobak R. Azamian, through his living trust, sold 10,000 shares of common stock on June 17, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were executed in two tranches at weighted average prices of $61.24 and $61.81. Despite these sales, Azamian retains a significant stake, holding 847,991 shares indirectly and 33,421 shares directly.
Tarsus Pharmaceuticals director sells $776,495 in company stock
A director at Tarsus Pharmaceuticals (NASDAQ:TARS), William J Link, PhD, sold 12,500 shares of company stock for a total of $776,495 on June 15, 2026, executed through a pre-established trading plan. Despite this insider sale, the company has seen a 52% return over the past year and recently surpassed analyst expectations for its first-quarter 2026 earnings and revenue. Tarsus Pharmaceuticals maintains a strong balance sheet with more cash than debt, though it is not yet profitable.
Tarsus Pharmaceuticals director sells $183,384 in company stock
Katherine Goodrich, a director at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), sold 2,954 shares valued at $183,384 on June 15, 2026, under a Rule 10b5-1 trading plan. This transaction leaves her with 2,233 shares. The company recently reported better-than-expected Q1 2026 earnings and revenue, despite a slight aftermarket stock decrease.
Tarsus Pharmaceuticals Inc (TARS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Tarsus Pharmaceuticals Inc (TARS) dividend history and stock split information. It indicates that Tarsus Pharmaceuticals has not distributed any dividends over the past five years and has no recorded stock splits. The content is primarily a data placeholder on a financial information platform.
Tarsus director Katherine Goodrich sells $183k in stock
Tarsus Pharmaceuticals director Katherine Goodrich sold 2,954 shares valued at $183,384 on June 15, 2026, as part of an automatic trading plan. This transaction leaves her with 2,233 shares. The sale occurred while Tarsus shares trade near their fair value, following strong Q1 2026 earnings where the company exceeded analyst expectations for both EPS and revenue.
[Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity
Jeffrey S. Farrow, an officer at Tarsus Pharmaceuticals, Inc., reported insider trading activity as per a Form 4 filing. The activity involved the vesting of 27,881 Restricted Stock Units (RSUs) on June 15, 2026, and the subsequent sale of 14,396 shares at $60.95 each on June 16, 2026. This sale was a mandatory "sell to cover" transaction to fulfill tax withholding obligations, not a discretionary trade, leaving Farrow with 56,801 direct shares.
Tarsus (TARS) director Goodrich sells 2,954 shares in pre-planned trade
Tarsus Pharmaceuticals, Inc. director Katherine Goodrich sold 2,954 shares of common stock at $62.08 per share on June 15, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in February 2026. After this transaction, she directly holds 2,233 shares. This sale is considered administrative and routine, with limited implications for the company's investment case.
Tarsus Pharmaceuticals Inc (TARS) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Tarsus Pharmaceuticals Inc (TARS), noting its current valuation score of 9.65, ranking 11th out of 157 in the Pharmaceuticals industry. It highlights the company's P/E ratio of -56.18, which is significantly below its recent high and slightly above its recent low. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Tarsus Pharmaceuticals Inc (TARS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Tarsus Pharmaceuticals Inc (TARS), focusing on business segments. As of Q3 FY2025, the company reported $118.70 million in product revenue, though specific proportions for business and regional contributions have not yet been disclosed. The data highlights the overall revenue generated from products while noting the lack of detailed segmentation information.
[144] Tarsus Pharmaceuticals, Inc. SEC Filing
This SEC filing (Form 144) for Tarsus Pharmaceuticals, Inc. (TARS) details the proposed sale of 10,000 shares of common stock with an aggregate market value of $615,473.27. The shares were acquired via private placement in 2017 and are to be sold through Merrill Lynch on June 17, 2026. The filing indicates a neutral impact and sentiment according to StockTitan.
Tarsus (TARS) director Scott Morrison settles 2,954 RSUs into stock
Tarsus Pharmaceuticals director Scott W. Morrison had 2,954 Restricted Stock Units (RSUs) vest and settle into an equal number of common shares on June 12, 2026, at a price of $0.00 per share. This transaction was a routine equity compensation event and not an open-market trade. Following this, Morrison directly holds 7,638 shares and indirectly holds 6,016 shares through a family trust.
Tarsus Pharmaceuticals (TARS) director receives 2,954 shares from RSU vesting
Tarsus Pharmaceuticals director Katherine Goodrich acquired 2,954 common shares on June 12, 2026, through the settlement of vested Restricted Stock Units (RSUs) at a price of $0.00 per share. This transaction was an equity award vesting, not an open-market purchase, and increased her direct holdings to 5,187 shares of Tarsus common stock. No shares were sold or disposed of in this Form 4 filing.
Director Wendy Yarno gains 2,954 Tarsus (TARS) shares from RSU grant
Tarsus Pharmaceuticals director Wendy L. Yarno acquired 2,954 shares of common stock through the settlement of vested Restricted Stock Units (RSUs) granted in June 2025 as compensation for her non-employee director service. After this transaction, Yarno directly holds 16,654 shares of Tarsus Pharmaceuticals common stock. This event was not an open-market transaction but rather the conversion of RSUs into shares upon their one-year vesting anniversary.
Director at Tarsus (NASDAQ: TARS) settles 2,954 RSU-based shares
Tarsus Pharmaceuticals director Bhaskar Chaudhuri acquired 2,954 shares of common stock through the settlement of vested Restricted Stock Units (RSUs), a standard equity compensation event. Following this transaction, Chaudhuri directly holds 11,654 shares of Tarsus common stock. The RSUs were granted on June 12, 2025, and vested on the one-year anniversary, subject to continuous service as a non-employee director.
Tarsus Pharmaceuticals (NASDAQ: TARS) insider files to sell 12,500 shares
Tarsus Pharmaceuticals (NASDAQ: TARS) insider William J. Link has filed a Form 144 to sell 12,500 shares of common stock, which originated from a stock option exercise in 2017. The filing also notes a previous sale of 12,500 shares on March 16, 2026, generating proceeds of $859,787.14. This Form 144 serves as an administrative notice of intent to sell and does not specify the exact timing for the proposed sale.
[144] Tarsus Pharmaceuticals, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Tarsus Pharmaceuticals, Inc. (TARS), indicating a proposed sale of securities under Rule 144. The filing details the class of securities, number of shares, aggregate market value, and the acquisition nature (restricted stock vesting from the Issuer). It also provides recent news and SEC filings for Tarsus Pharmaceuticals.
Is Conference-Spotlighted XDEMVY Adoption Quietly Reshaping the Long-Term Narrative for Tarsus (TARS)?
Tarsus Pharmaceuticals recently presented at the William Blair and Jefferies healthcare conferences, emphasizing the growing real-world adoption of its eye-care product, XDEMVY, supported by direct-to-consumer marketing. While XDEMVY's momentum is positive, the company's reliance on a single product and associated high commercial costs create tension. Tarsus is also diversifying with a Phase 2 study for TP-05 in Lyme disease prevention, aiming to reduce its dependence on XDEMVY.
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns
Tarsus Pharmaceuticals (TARS) has experienced recent share price weakness, with its stock down 18.32% over 90 days and 26.16% year-to-date, despite strong long-term returns. Analysts suggest TARS is undervalued, with a fair value pegged at $88.00 against its current trading price of $59.64, hinting at a potential buying opportunity. However, risks remain, including competition and pricing pressure, which investors should consider alongside the growth potential.
Is Conference-Spotlighted XDEMVY Adoption Quietly Reshaping the Long-Term Narrative for Tarsus (TARS)?
Tarsus Pharmaceuticals recently highlighted the growing adoption of its eye-care product, XDEMVY, at two major healthcare conferences, emphasizing its commercial progress and direct-to-consumer marketing efforts. While XDEMVY remains the primary revenue driver, the company is also diversifying with its TP-05 pipeline project for Lyme disease prevention, aiming to reduce single-product dependence. Despite projected revenue growth and a high fair value estimate for Tarsus, investors are cautioned to consider the heavy commercial spend and alternative, more pessimistic analyst forecasts.
Clearbridge Investments LLC Cuts Stake in Tarsus Pharmaceuticals, Inc. $TARS
Clearbridge Investments LLC reduced its stake in Tarsus Pharmaceuticals, Inc. by 10.7% in the fourth quarter, selling over 60,000 shares but still owning more than half a million shares valued at $41.4 million. The company's stock rose 3.2%, and it exceeded revenue and EPS expectations in its latest quarterly report. Analyst sentiment for Tarsus Pharmaceuticals remains positive, with a "Moderate Buy" consensus rating and an average price target of $90.67, despite some insider share sales.
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns
Tarsus Pharmaceuticals (TARS) has experienced recent share price weakness, with its stock down over the past 90 days and year-to-date, despite strong longer-term returns for earlier investors. The company is currently trading at a discount to analyst and intrinsic values, with a fair value estimate of $88, suggesting it is 32.2% undervalued. However, investors are cautioned to consider risks such as reliance on XDEMVY and potential pricing pressures.
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen
Wall Street Zen has upgraded Tarsus Pharmaceuticals (NASDAQ:TARS) from "hold" to "buy," contributing to a positive analyst outlook, despite one recent "sell" rating among a "Moderate Buy" consensus. The company also surpassed its latest quarterly earnings and revenue expectations. Recent insider transactions show both selling and buying activity, while institutional investors have adjusted their positions in the stock.
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
William Blair has reiterated its Buy rating on Tarsus Pharmaceuticals (TARS.US). The article does not provide further details or a price target.
TARS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of Tarsus Pharmaceuticals Inc (TARS), focusing on its revenue breakdown, profitability margins, and a comparison with its competitors. TARS exhibits a strong gross margin of 94.20%, but negative operating and net margins, along with a negative Return on Equity, indicate challenges in converting operations to shareholder value. The company's competitive standing is evaluated against IDYA and DFTX based on market capitalization and efficiency metrics.
Evaluating Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness
Tarsus Pharmaceuticals (TARS) has experienced a recent stock price decline, down 7% over the past month and 22% over three months. Despite this, the company is considered undervalued with a fair value of $95.11 compared to its current price of $59.40, driven by its pipeline expansion and international growth opportunities. The valuation hinges on successful execution in eye care and infectious disease programs, with potential risks if XDEMVY uptake disappoints or high marketing costs persist.
Evaluating Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness
Tarsus Pharmaceuticals (TARS) has experienced a recent stock price decline, down 7% in the past month and 22% over three months. Despite this, the company is evaluated as 37.5% undervalued, with a narrative fair value of approximately $95.11 compared to its current price of $59.40. This valuation hinges on successful execution in eye care and infectious disease programs, pipeline expansion, and international growth opportunities for its product XDEMVY.
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference on June 2nd, and the 2026 Jefferies Global Healthcare Conference on June 3rd. Management will present at both events, with live webcasts and replays available on the company's website. The company is known for its FDA-approved XDEMVY for Demodex blepharitis and is developing therapies for ocular rosacea and Lyme disease.
Assessing Tarsus Pharmaceuticals (TARS) Valuation After New TP-05 Phase 2b Lyme Disease Trial Update
Tarsus Pharmaceuticals (TARS) recently updated investors on its Phase 2b trial for TP-05, an oral tablet for Lyme disease prevention. Despite a year-to-date share price decrease of 21.41%, the stock has seen a 1-year total shareholder return of 47.73% and is considered 33.3% undervalued by a popular narrative, with a fair value target of $95.11 against its current $63.48. The company's future growth hinges on the continued traction of XDEMVY and efficient conversion of revenue into profit.
Assessing Tarsus Pharmaceuticals (TARS) Valuation After New TP-05 Phase 2b Lyme Disease Trial Update
Tarsus Pharmaceuticals (TARS) is in focus after providing an update on its Phase 2b trial for TP-05, a potential Lyme disease preventative. Despite a year-to-date dip, the stock shows strong long-term returns and is considered 33.3% undervalued at its current price of $63.48, against a narrative fair value of $95.11. The valuation hinges on the continued success and adoption of its product XDEMVY, with potential risks tied to high SG&A and product concentration.
